Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALFQ adjuvant
- Development stage
- Unknown
- Lead developer
- Walter Reed Army Institute of Research
- Administration
- Intradermal, Intramuscular
01
Overview
ALFQ adjuvant (Army Liposome Formulation with QS21) is a liposome-based vaccine adjuvant developed by the U.S. Army at the Walter Reed Army Institute of Research (WRAIR). It belongs to the Army Liposome Formulation (ALF) family of adjuvants and is formulated by combining high-cholesterol ALF liposomes containing saturated phospholipids (DMPC and DMPG) with the saponin QS-21 and synthetic monophosphoryl lipid A (MPLA) as an immunostimulant. ALFQ is designed to enhance and direct immune responses, promoting mixed Th1/Th2 antibody responses and augmenting functional antibody activity. It is being evaluated in clinical trials as an adjuvant component for various vaccines, including candidates for malaria, HIV-1, COVID-19, Campylobacter jejuni diarrhea, and dengue (such as VLP Therapeutics' VLPDEN-02).
- Other names
- ALFQArmy Liposome Formulation + QS21Army Liposome Formulation with QS21
02
Targets
MYD88 (Myeloid differentiation primary response protein MyD88)TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on ALFQ adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALFQ adjuvant.